https://www.optimumcomms.com/wp-content/uploads/2023/12/Vesper_Bio_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-31 08:15:102025-10-31 13:02:50Vesper Bio announces positive Phase Ib/IIa topline results for lead candidate VES001 for frontotemporal degeneration
https://www.optimumcomms.com/wp-content/uploads/2024/02/Alys_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-30 08:30:452025-10-30 08:30:45Alys Pharmaceuticals doses first subject in Phase 1/1b trial of ALY-301, a first-in-class mast cell selective c-Kit inhibitor for Chronic Urticaria
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-30 06:03:032025-10-30 06:03:03Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-29 17:13:252025-10-29 17:13:25Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results
https://www.optimumcomms.com/wp-content/uploads/2023/09/WiLD_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-28 09:04:042025-10-28 09:04:04Women in Life Science Denmark (WiLD) expands mentoring program to support next generation of female leaders in life sciences
https://www.optimumcomms.com/wp-content/uploads/2025/02/Domain_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-28 08:40:512025-10-28 08:40:51Domain Therapeutics Doses First Patients in Phase I / II Trial of DT-7012 Targeting CCR8 in Solid Tumors
https://www.optimumcomms.com/wp-content/uploads/2023/02/ViCentra_Logo_300x180px-3.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-28 08:30:232025-10-28 08:30:23ViCentra Strengthens Leadership Team to Accelerate Growth
https://www.optimumcomms.com/wp-content/uploads/2025/09/AMS.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-27 08:51:022025-10-27 08:51:02AMS to participate in upcoming investor conferences in November and December
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-23 08:59:002025-10-23 08:59:20Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
https://www.optimumcomms.com/wp-content/uploads/2025/03/Novo_Holdings23_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-21 14:54:522025-10-21 14:54:52Novo Holdings to make changes to its Board of Directors
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-21 14:53:072025-10-21 14:53:07The Novo Nordisk Foundation proposes new candidates for election as members of the Board of Directors of Novo Nordisk A/S
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-21 14:31:382025-10-24 16:27:46Biocomposites launches SYNICEM™ spacers in the U.S.
https://www.optimumcomms.com/wp-content/uploads/2023/08/Astraveus.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-21 08:34:142025-10-21 08:34:14Astraveus further strengthens world class leadership team to advance development of Lakhesys Benchtop Cell Factory™
https://www.optimumcomms.com/wp-content/uploads/2025/03/Novo_Holdings23_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-21 08:32:362025-10-21 08:32:36Novo Holdings co-leads €40m fundraising to scale MATR Foods’ production of organic plant-based meat alternatives
https://www.optimumcomms.com/wp-content/uploads/2025/10/Mission_Therapeutics_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-15 09:06:302025-10-15 09:06:30Mission Therapeutics raises $13.3 million to progress first-in-class Parkinson’s disease candidate MTX325 through clinical trials
https://www.optimumcomms.com/wp-content/uploads/2025/07/Actithera-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-14 08:32:542025-10-14 08:32:54Actithera Secures Exclusive Rights to Innovative Covalent Chemistry Technologies from Weizmann Institute for Targeted Radiopharmaceutical Applications
https://www.optimumcomms.com/wp-content/uploads/2025/01/Ona_Therapeutics_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-14 08:30:322025-10-14 08:33:36Ona Therapeutics Appoints Oncology Drug Development Veteran Dr. Antoine Yver as Chair to Accelerate ADC Programs to Clinical Inflection Points
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-10 09:12:332025-10-10 09:12:33Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler–Najjar syndrome who are immune to AAV
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-09 10:50:182025-10-10 10:24:10Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
https://www.optimumcomms.com/wp-content/uploads/2025/10/Glen-Clova_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-09 09:21:542025-10-09 15:06:52Glen Clova Scientific Announces Clinical Advisory Board for its Immuno-Dermatology PipelineFor more information about Optimum Strategic Communications, please get in touch.
